A phase I study to establish the safety and tolerability of ARC1905 (Anti-C5 Aptamer) in subjects with dry age-related macular degeneration 31/12/2011
The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injections in subjects with geographic atrophy secondary to dry age-related macular degeneration(AMD). Patients were assigned in an alternating fashion to one of two dose levels of ARC1905: 0.3 or 1 mg/eye. Patients were treated with 3 initial intravitreal injections of ARC1905 at Day 0,Week 4,Week 8, and a followup visit at Week 16. They then received 2 subsequent injections at Week 24 and Week 36, with a final follow-up visit at Week 48. There was a maximum of 5 ARC1905 injections.
RESULTS: Pending analysis data. No safety concerns in this phase I intravitreal use for the first time of aptamer anti C5 for geographic atrophy.
Dr. Jordi Monés, M.D., Ph.D.
COMB Medical license number: 22.838
Doctor of Medicine and Surgery
Specialist in Ophthalmology
Specialist in Retina, Macula and Vitreorretinal